News

The trial will include patients with resistant strains of disease including methicillin-resistant Staphylococcus aureus (MRSA). “We have enrolled more than 1,800 patients overall and expect to have more

The single center phase IIa study is a placebo-controlled, parallel group study designed to evaluate the safety, preliminary efficacy, and pharmacokinetics of two 14-day dosing cycles in obese

Cesamet is a synthetic version of cannabis that is thought to interact with the cannabinoid receptor, CB1, which is present throughout the nervous system and is involved in

The newly-released data indicates that at 29 to 34 months after initial treatment, there was highly significant symptomatic improvement. There were no serious safety issues reported in individuals

The trial, targeted to commence in the third quarter of this year, is a 12 month, double blind, placebo-controlled trial and will enroll up to 215 patients with

In the study, which enrolled 887 patients, 73% of patients receiving Lexiva/ritonavir maintained suppression of viral replication after 48 weeks of dosing, compared with 71% of patients receiving

The agency determined that indiplon 5mg and 10mg capsules are 'approvable' but considered the all-important 15mg extended release version of the drug to be 'not approvable.' The rejection

In addition to its existing indication for the treatment of de-novo lesions in native coronary arteries, the Taxus liberte stent system is now indicated in Europe for the

The FDA informed the company that it will most probably require a dose-ranging study on subcutaneously administered DX-88 in order to support the company's application for approval. Dyax,